论文部分内容阅读
目的:探究丹参酮ⅡA注射液联合前列地尔治疗糖尿病肾病的临床疗效。方法:选取我院于2014年10月至2015年10月期间收治的糖尿病肾病患者100例为研究对象,按照随机数字表法分为研究组和对照组各50例;对照组给予前列地尔,研究组给予前列地尔与丹参酮ⅡA注射液,比较两组患者总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)以及血尿素氮(BUN),24 h尿蛋白定量及肌酐(Cre)的水平。结果:治疗前两组患者间各项指标均无显著性差异(P>0.05);治疗后两组患者TC、TG、LDL-C、Cre、BUN、24 h尿蛋白定量较治疗前均出现明显降低,HDL-C较治疗前明显升高(P<0.05);研究组患者TC、TG、LDL-C、Cre、BUN、24 h尿蛋白定量均低于对照组,HDL-C高于对照组(P<0.05);两组患者均未出现严重不良反应。结论:丹参酮ⅡA注射液联合前列地尔治疗糖尿病肾病可以改善患者的血脂水平,降低肌酐,尿蛋白,缓解肾脏损伤,具有明显的临床疗效。
Objective: To investigate the clinical efficacy of tanshinone Ⅱ A injection combined with alprostadil in the treatment of diabetic nephropathy. Methods: One hundred patients with diabetic nephropathy who were treated in our hospital from October 2014 to October 2015 were selected as the research object. According to the random number table, 50 cases were divided into study group and control group. The control group was given prostaglandin, The study group was given alprostadil with tanshinone Ⅱ A injection. The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL- BUN, 24 h urinary protein and Cre creatinine were measured. Results: There was no significant difference in each index between the two groups before treatment (P> 0.05). After treatment, the urinary protein levels of TC, TG, LDL-C, Cre, BUN and 24 h were significantly higher than those before treatment (P <0.05). The urinary protein levels of TC, TG, LDL-C, Cre, BUN and 24 h in study group were lower than those in control group, and HDL-C was higher than that in control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion: Tanshinone Ⅱ A injection combined with alprostadil for the treatment of diabetic nephropathy can improve the level of serum lipids, reduce creatinine and urinary protein and relieve renal injury, with obvious clinical curative effect.